Request Sample Inquiry
Orphan Drugs Market

Orphan Drugs Market

Orphan Drugs Market Global Industry Assessment & Forecast

# Pages:


Base Year:


Nov - 2021


Report Code:


Segments Covered
  • By Disease Type Oncologic Diseases, Metabolic Diseases, Hematologic & Immunologic Diseases, Infectious Diseases, Neurologic Diseases, Other Rare Diseases
  • By Indication Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Graft vs Host Disease, Renal Cell Carcinoma, Others
Forecast YearsForecast Years: 2021 - 2028
Historical YearsHistorical Years: 2016 - 2020
Revenue 2021Revenue 2021: 112.36 Billion
Revenue 2028Revenue 2028: 3199.3 Billion
Revenue CAGRRevenue CAGR (2021 - 2028): 7.4
Fastest Growing Region Fastest Growing Region (2022 - 2028) North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics
  • Region Level Market Share
  • Import Export Analysis
  • Production Analysis
  • Others Request Customization Speak To Analyst

Research Methodology: Orphan Drugs Market - Global Market Assessment, 2021 - 2028

The global Orphan Drugs market research study is based on a comprehensive research methodology that involves 3 major activities: Secondary Research, Primary Research, and Data Triangulation. Secondary resources are utilized to gain insights on the market and later primary research is conducted to revalidate the information and conclusion derived from the secondary research. Moreover, the information procured from the secondary and primary resources is undergone through data triangulation methods to attain more accurate results on quantitative and qualitative analysis for specific market research studies. 

Secondary Research

Primary Research:

The later stage covers data validation and collection from primary research. The information gained/procured from the secondary data sources is validated through extensive primary interviews with industry experts across the Orphan Drugs supply chain. The primary research is also conducted to identify key players in the market and to gather and validate already procured information pertaining to their market-specific financial information. Moreover, primary research is used to gain/validate information about:

  • Orphan Drugs market size at regional and country level
  • Key industry players and their market share and Orphan Drugs market-specific sales/revenue
  • Understanding of the Orphan Drugs supply chain and overall ecosystem

Data Triangulation and Market Size Estimations

After arriving at the global market numbers, top-down and bottom-up approaches are used to estimate, validate and finalize the market size of the Orphan Drugs market. After the determination of the overall market size, the market is divided into various segments and sub-segments. Moreover, these same approaches mentioned above were used to derive and estimate market numbers for mentioned segments/sub-segments in the market. During the data triangulation process, the data was analyzed by employing various data models and statistical techniques to arrive at exact statistics and market size for each segment/sub-segment of the market.  The data is analyzed and triangulated by considering all the key market impacting factors from both supply and demand side of Orphan Drugs market. 

Frequently Asked Question
  • The global Orphan Drugs valued at 112.36 Billion in 2020 and is expected to reach 3199.3 Billion in 2028 growing at a CAGR of 7.4%.

  • The prominent players in the market are RegeneRX Biopharmaceuticals Inc., F.Hoffman-La Roche AG, Pfizer Inc., Shire PLC, AbbVie Inc., Alexion, Bayer, Celgene Corporation, Johnson & Johnson Services Inc., Sanofi, Novartis AG, Merck & Co. Inc., Amryt Pharma PLC, Brisol-Myers Squibb Company..

  • The market is project to grow at a CAGR of 7.4% between 2021 and 2028.

  • The driving factors of the Orphan Drugs include

    • Demand has increased substantial for the orphan drugs due to surge in occurrence of rare diseases. Furthermore, the increase in awareness with respect to rare diseases among the populace, rise in investment in R&D, and drug development is fueling the market growth.
    • Rising healthcare spending nd improving healthcare infrastrcture is another driving factor for the market.

  • North America was the leading regional segment of the Orphan Drugs in 2020.